Pink Sheet reporters and editors discuss the dismissal of PhRMA’s suit challenging the Medicare price negotiation provisions (:30), the US FTC and HHS investigation of drug shortages (12:01), and the potential for FDA-approved marijuana products (23:47).

More On These Topics From The Pink Sheet

PhRMA’s Lawsuit Against Medicare Trips Over ‘Administrative Remedy’ Standard; Will Others? https://pink.citeline.com/PS149791/PhRMAs-Lawsuit-Against-Medicare-Trips-Over-Administrative-Remedy-Standard-Will-Others 

FTC, HHS Probe GPO Contracting Practices As Source Of Generic Drug Shortages: https://pink.citeline.com/PS149790/FTC-HHS-Probe-GPO-Contracting-Practices-As-Source-Of-Generic-Drug-Shortages 

Prescription Marijuana? FDA Rescheduling Memo Sets Stage To Test Whether There’s A Viable Market: https://pink.citeline.com/PS149781/Prescription-Marijuana-FDA-Rescheduling-Memo-Sets-Stage-To-Test-Whether-Theres-A-Viable-Market

Drug Fix: Price Negotiation Suit Tossed, Drug Shortage Probe, FDA-Approved Marijuana

The Association of the European Self-Care Industry celebrates its 60th birthday this year. In this episode, we catch up with AESGP director general, Jurate Švarcaite, to find out how the association will mark the occasion, including at this year’s Annual Meeting in Brussels in June. AESGP Annual Meetings are an excellent way to find out what the key issues and trends are impacting the European consumer health industry, and this one will be no different. We talk through some of the key themes of this year’s conference. Sustainability continues to be a mega-trend, closely followed by digitalization and artificial intelligence. With its wide-ranging footprint across OTC medicines, food supplements and self-care medical devices sectors, the consumer health industry is facing an avalanche of regulations, and the AESGP continues to be an effective advocate for its stakeholders, alongside adjacent industry partners.

AESGP’s 60th Birthday Celebrations In 2024 Including Annual Meeting, With Jurate Švarcaite

Pink Sheet reporters and editors discuss the FDA’s approach to psychedelic drugs (:25), whether postmarket clinical trial data from the Alzheimer’s drug Aduhelm will be published (16:32), and the FDA offering more time to find candidates for its new Genetic Metabolic Diseases Advisory Committee (27:19).

More On These Topics From The Pink Sheet

Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance: https://pink.citeline.com/PS149813/Lykos-MDMA-NDA-Leads-Upcoming-Tests-Of-US-FDAs-Psychedelics-Draft-Guidance 

For Psychedelics, US FDA Is Open To Creative Thinking But Firm On Approval Standards: https://pink.citeline.com/PS149812/For-Psychedelics-US-FDA-Is-Open-To-Creative-Thinking-But-Firm-On-Approval-Standards 

A Visual Trip Through The Psychedelic Pipeline: https://pink.citeline.com/PS149831/A-Visual-Trip-Through-The-Psychedelic-Pipeline 

Aduhelm’s Post-Marketing Studies: At Least One More Data Dump Likely Required By NIH: https://pink.citeline.com/PS149826/Aduhelms-Post-Marketing-Studies-At-Least-One-More-Data-Dump-Likely-Required-By-NIH 

New US FDA Genetic Metabolic Adcomm Needs More Candidates: https://pink.citeline.com/PS149819/New-US-FDA-Genetic-Metabolic-Adcomm-Needs-More-Candidates

Drug Fix: US FDA And Psychedelic Drugs, Aduhelm Clinical Trial Data, Adcomm Candidates

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.
https://scrip.citeline.com/SC149846/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 26 February 2024

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. The company is focused on developing drugs that inhibit the NLRP3 inflammasome, a validated drug target that plays a pivotal role in controlling inflammatory diseases. It has two clinical trials ongoing – both Phase Ib/IIa – in Parkinson’s disease and for cardiovascular risk in obese patients.

NodThera On The Role Of The Brain In Driving Chronic Disease

Emma and Flora outline expected trends and exciting upcoming events across therapy areas for 2024, straight from the subject matter experts at Datamonitor.

Other platforms (in addition to SoundCloud):​

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

February Datamonitor Podcast: 2024 Clinical Outlook

In this episode of Over the Counter, HBW Insight speaks to Paul LaTerra, Director, R&D, Global Hair and Scalp for Kenvue, a New Jersey-based consumer health company that markets skin care brands Neutrogena, Aveeno and Lubriderm. We discuss growth of the beauty-from-within supplements market, how the products complement topical skin care and hair formulas and the growing body of research demonstrating significant skin and hair health benefits.

Voice Recorder

The Emerging Benefits Of ‘Beauty-From-Within,’ Featuring Kenvue’s Paul LaTerra

iRhythm CEO Quentin Blackford returns to Medtech Insight’s Cardio Conversations podcast to talk about the launch of the company’s new Monitor long-term cardiac monitoring patch, the company's plans for the MCT market, and a lot more.

Cardio Conversations: iRhythm CEO Blackford Talks AI Arrhythmia Diagnostics

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.
https://scrip.citeline.com/SC149879/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 4 March 2024

In this episode, US regulatory reporter Hannah Daniel speaks to Ocutrx CEO Michael Freeman about augmented reality in medical products and their not-so-unique regulatory requirements.

Medtech Connect Episode 13: Augmented Reality In Surgery

2024년 글로벌 전문가들이 예측하는 치료영역의 발전은 무엇인 지에 대한 Scrip 기사를 요약한 내용입니다
https://scrip.citeline.com/SC149780/Scrip-AsksWhat-Does-2024-Hold-For-Biopharma-Part-6-Therapeutic-Area-Advances

Scrip이 묻다: 2024년 제약바이오업계 전망은? 치료영역의 발전 (Korean-language podcast)

Pink Sheet reporters and editor discuss Vanda’s decision to sue the FDA over the rejection of the Hetlioz jet lag indication (:30), Mark Cuban’s comments at a White House event that the federal government and others should stop doing business with the big three PBMs (11:50), and the cut in non-user fee dollars in the FY 2024 FDA appropriations bill (24:49).

More On These Topics From The Pink Sheet

Vanda Appeals FDA’s Denial Of Hetlioz Jet Lag Application As It Is Hit With CRL For Insomnia: https://pink.citeline.com/PS149914/Vanda-Appeals-FDAs-Denial-Of-Hetlioz-Jet-Lag-Application-As-It-Is-Hit-With-CRL-For-Insomnia 

Mark Cuban: Pharma’s Secret Weapon In The Fight Against PBMs: https://pink.citeline.com/PS149899/Mark-Cuban-Pharmas-Secret-Weapon-In-The-Fight-Against-PBMs 

Congress Gives US FDA Austere Budget But Seeks Boosts On Inspections, IT, And ALS Activities: https://pink.citeline.com/PS149897/Congress-Gives-US-FDA-Austere-Budget-But-Seeks-Boosts-On-Inspections-IT-And-ALS-Activities

Drug Fix: Vanda Appeals US FDA Jet Lag Denial In Court, Mark Cuban Battles PBMs, Austere FDA Budget

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.

Links to the stories discussed are here: https://scrip.citeline.com/SC149924/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 11 March 2024

Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about the value of identifying the 80% of patients with undiagnosed or misdiagnosed conditions, and how his company is addressing this need.

"Identifying The 80% Of Undiagnosed And Misdiagnosed Patients"

Summary: 今回取り上げた記事はこちら
「MindMed Ready To Take LSD Therapy Into Phase III For Anxiety（MindMed、LSD療法を不安症治療の第III相治験へ）」

https://www.citeline.com/ja-jp/resources/mindmed-ready-to-take-lsd-therapy-into-phase-iii-for-anxiety
※全文の閲覧には情報の登録（無料）が必要です。

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。
(英語版)
https://scrip.citeline.com/SC149912/MindMed-Ready-To-Take-LSD-Therapy-Into-Phase-III-For-Anxiety
※全文の閲覧には購読（有料）が必要です。

世界の製薬ビジネスメディアScrip（スクリップ）とは？
https://www.citeline.com/ja-jp/products-services/commercialization/scrip

【3分で解説  世界のファーマ】第17回 LSDで不安症を治療 第III相開始へ (Japanese-language podcast)

Over The Counter 18 March 2024 1

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
https://scrip.citeline.com/SC149962/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 18 March 2024

Listen to the podcast via the player below:

Medtech Insight articles addressing topics discussed in this episode:

In Five Years, People Will Navigate Their Health Care With An AI-Advisor – Verily’s Andrew Trister

Verily’s Andrew Trister On Uniting The Pieces To Create Personalized Health, Equity

European Parliament Adopts AI Act, But Success Hangs On The AI Office

AI Clinical Summarization Tools Sit In 'Regulatory Grey Area', Experts Warn

Digital Health Roundup: EU’s AI Act Impact; Verily's Andrew Trister’s Vision For Personal AI Agent

Guest speaker Kevin Duan joins Brian Yang and Dexter Yan to discuss the proposed US BIOSECURE Act, the US FDA's approval of a China-origin anti-PD-1 drug and the latest developments in the antibody-drug conjugate area.

China Biotech Podcast (Chinese language) - March 2024

Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access (:34), the SCOTUS reaction to the fight against misinformation (18:28), and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews (31:23).

More On These Topics From The Pink Sheet

Mifepristone Supporters Highlight Voter Trust In FDA Decisions Ahead Of Supreme Court Arguments: https://pink.citeline.com/PS149998/Mifepristone-Supporters-Highlight-Voter-Trust-In-FDA-Decisions-Ahead-Of-Supreme-Court-Arguments 

US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments: https://pink.citeline.com/PS149985/US-FDAs-Anti-Misinformation-Campaigns-Look-Safer-After-Supreme-Court-Oral-Arguments 

The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews: https://pink.citeline.com/PS149961/The-Dog-That-Didnt-Bark-ODAC-Gives-Nod-To-Three-Products-Despite-Negative-FDA-Reviews 

Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts: https://pink.citeline.com/PS149995/Eye-On-ODAC-Former-Members-FDAs-Pazdur-Talk-PreMeeting-Mindsets-Impact-Of-Sponsors-Experts

Drug Fix: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
https://scrip.citeline.com/SC150008/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 26 March 2024

Flora and Ian are joined by Datamonitor’s financial analyst Abby, who discusses the Inflation Reduction Act and drug pricing trends in the US.
Other platforms (in addition to SoundCloud):​
Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​
Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​

​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

​Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

March Datamonitor Podcast 2024: The US Inflation Reduction Act

In this episode, HBW Insight’s Europe and US editors Tom Gallen and Malcolm Spicer bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago, Kenvue, soon to celebrate its first anniversary as a new company; Sanofi, which has announced it will be exiting the OTC market by divesting its OTC business and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the possible advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.

Analysing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.
https://scrip.citeline.com/SC150030/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 1 April 2024

기술 수요와 공급의 '불균형' 속에서 국내 ADC 업체들은 생태계를 발전시키려 노력하고 있습니다.  Scrip의 정두영 피노바이오 대표 인터뷰기사를 요약한 내용입니다.
https://scrip.citeline.com/SC149716/How-Pinotbio-Is-Helping-Build-Koreas-ADC-Ecosystem

피노바이오, 국내 ADC 생태계 발전에 기여할 것 (Korean-language podcast)

In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to industry professionals at the Healthcare Information and Management Systems Society (HIMSS) 2024 conference about what they enjoy about the annual gathering and what excites them for the future.

Medtech Connect Episode 14: Live From HIMSS 2024

Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed (:32), an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees (9:08), and Japan’s PMDA opening an office in Washington D.C. (16:19).

More On These Topics From The Pink Sheet

Amylyx’s Relyvrio Withdrawal May Trigger More Public Pledges Based On Confirmatory Trial Data: https://pink.citeline.com/PS150060/Amylyxs-Relyvrio-Withdrawal-May-Trigger-More-Public-Pledges-Based-On-Confirmatory-Trial-Data 

US FDA Envisions Advisory Committees For Allergy, Asthma Biomarkers With ‘Real Impact’: https://pink.citeline.com/PS149915/US-FDA-Envisions-Advisory-Committees-For-Allergy-Asthma-Biomarkers-With-Real-Impact 

Breaking Barriers: Japan's PMDA To Open First Global Office, In D.C.: https://pink.citeline.com/PS150044/Breaking-Barriers-Japans-PMDA-To-Open-First-Global-Office-In-DC

Drug Fix: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA

Audio roundup of selected biopharma industry content from Scrip over the business week ended 5 April 2024. In this episode: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
https://scrip.citeline.com/SC150062/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 8 April 2024

In this episode, In Vivo speaks to 2024 Rising Leader Hanadie Yousef, CEO of Juvena Therapeutics, about her journey, the secretome as a source of therapeutics, longevity medicine and alternatives to GLP-1 inhibitors for obesity.

In Conversation With 2024 In Vivo Rising Leader, Hanadie Yousef

Scrip’s senior editor Vibha Ravi speaks with Jack Hoppin, CEO and chairman, and John Babich, chief scientific officer, at Ratio Therapeutics, about the company’s radiopharmaceuticals pipeline, investment by BMS, use of AI, trends and developments in radiopharma research like combining ADCs or PARP inhibitors and more.
https://scrip.citeline.com/SC150098/Ratio-Therapeutics-On-BMS-Investment-Radiopharma-RD-Trends-AI-Use

Ratio Therapeutics On BMS Buy-In, Radiopharma R&D Trends, AI And Assets

Learn how molecular technology is enhancing patient safety for CAR-T clinical trials. 

US FDA recently initiated class safety labeling changes after evaluating the safety of CAR-T cancer treatment therapies. What does this mean for developers in the CAR-T landscape? Listen to your free podcast to find out.

Listen in on the conversation as experts from Cerba discuss facilitating patient safety measures in CAR-T therapies by accurately identifying the integration of viral vectors, utilizing flow cytometry, and more.

Listen now as experts discuss answers to:  
· What patient monitoring is required by the FDA?
 · What molecular technology does Cerba use and how does it meet FDA requirements?
 · What is the importance of cytometry assays in monitoring CAR-T cells? 
· What are the opportunities for combining flow cytometry with genomic solutions? 
· What key innovations are poised to improve patient monitoring in clinical trials?

Podcast: Facilitating Patient Monitoring in CAR-T Development

2024 Global Generics & Biosimilars Awards

Audio roundup of selected biopharma industry content from Scrip over the business week ended 26 April 2024. In this episode: 2023’s top selling drugs and the COVID cliff; falling sales force Roche to reassess priorities; Phase III immunology win for Sanofi; BMS’s strong pipeline: and which companies could be acquired next.
https://scrip.citeline.com/SC150182/Quick-Listen-Scrips-Five-MustKnow-Things

Scrip's Five Must-Know Things - 30 April 2024

Flora and Emma are joined by Datamonitor’s CNS analysts Summer, Joseph, and Wen-Yu to discuss coverage from AAN.

Other platforms (in addition to SoundCloud):​

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

April Datamonitor Podcast 2024: AAN coverage

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights key interviews with Philips’ CEO Roy Jakobs on NAM’s draft framework on AI, BD’s CTO Beth McCombs R&D initiatives and HSS spine co-chair Sheeraz Qureshi on his vision for integrating AI tech. Hannah Daniel discusses the FDA’s new initiative to create an idea lab for medical device use at home and Apple Watch’s new feature to help people with Parkinson’s disease.

Listen to the podcast via the player below:

Medtech Insight articles addressing topics discussed in this episode:

BD’s CTO Beth McCombs Discusses Key Initiatives – AI/Gen AI; DE&I Strategy; Succession Planning

HSS Spine Surgeon Sees Potential For AI Chatbots, But Not To ‘Practice Medicine’ 

Philips Portfolio Includes ‘No Single Product That Does Not Use A Type of AI,’ Says CEO and AI Thought Leader Roy Jakobs

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

CDHR’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch

Pink Sheet reporter and editors discuss what an upcoming listening session means for the FDA’s advisory committee reform effort (:32), the agency’s efforts to help the clinical trial modeling and simulation industry (16:22), and the UK’s MHRA plan to use artificial intelligence to assist in drug application reviews (21:05).

More On These Topics From The Pink Sheet  

US FDA Adcomm Reform: Does Listening Session Suggest No Major Near-Term Changes?: https://pink.citeline.com/PS150167/US-FDA-Adcomm-Reform-Does-Listening-Session-Suggest-No-Major-Near-Term-Changes  

US FDA Wants Advice About Advisory Committees: Try Having Some?: https://pink.citeline.com/PS154644/US-FDA-Wants-Advice-About-Advisory-Committees-Try-Having-Some 

US FDA Developing Model Master File System To Grow Modeling, Simulation Field: https://pink.citeline.com/PS154647/US-FDA-Developing-Model-Master-File-System-To-Grow-Modeling-Simulation-Field 

UK’s MHRA To Use AI In Regulatory Review Process & RWD Analysis: https://pink.citeline.com/PS154643/UKs-MHRA-To-Use-AI-In-Regulatory-Review-Process--RWD-Analysis
More podcasts from the Pink Sheet: https://soundcloud.com/citelinesounds/sets/podcasts-from-the-pink-sheet?si=a64a3c5c834a470ca9e71dc19777df04&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing

Drug Fix: US FDA Adcomm Reform, A Boost For Clinical Trial Modeling, AI For Drug Review

Audio roundup of selected biopharma industry content from Scrip over the business week ended 3 May 2024. In this episode: Japan’s Ono buys US oncology firm; strong growth but supply issues for Lilly; Novo and Lilly make their money work; BMS cuts jobs, costs; and Big Pharma’s support for bioventures.
https://scrip.citeline.com/SC150211/Quick-Listen-Scrips-Five-MustKnow-Things
More podcasts in this series: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things?si=17107bcf40ad4c54b5148e7f58f28b69&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing

Scrip's Five Must-Know Things - 7 May 2024

In this episode, HBW Insight chats with sustainable packaging expert Tony Perrotta about why it’s so difficult to replace plastic pill packs in medicines packaging. Perrotta works for PA Consulting, which set up the Blister Pack Collective alongside consumer healthcare partners Haleon, Bayer and Sanofi. They are working with PulPac, which has invented a dry molded fiber alternative to plastic, which the collective hopes will be ready to commercialize in the next 12-24 months. We discuss whether regulators will accept such alternatives, given the safety and stability requirements for medicines, and the challenges of recycling, given the multitude of different frameworks and processes across the world. Perrotta also reveals that one of the partners in PA Consulting’s Bottle Collective, which also hopes to use the same dry molded fiber technology to replace plastic bottles in food, personal care and consumer health industries, will soon be launching its first market trial.

Solving The Sustainable Pill Pack Puzzle, With PA Consulting’s Tony Perrotta

In this episode, Medtech Insight senior reporter Hannah Daniel speaks to Mark Brown, Global Managing Director of Digital Trust Consulting at the British Standards Institute about digital trust. In a world of cybersecurity breaches and ransomware attacks on hospitals, digital trust between companies and consumers is key, but current siloed operations can hinder that. We talk about the EU’s AI act, the speed of digital transformation, cybersecurity incentives, and how principle-based regulations are better than prescriptive ones.

Episode 15: Digital Trust

Audio roundup of selected biopharma industry content from Scrip over the business week ended 10 May 2024. In this episode: AstraZeneca’s Vaxzevria farewell; the next wave of cardiometabolics; Pfizer recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer partners up for respiratory therapy.
https://scrip.citeline.com/SC150240/Quick-Listen-Scrips-Five-MustKnow-Things
Playlist: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Five Must-Know Things - 13 May 2024

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Citeline

Popular tracks